Brief: Sana Biotechnology Announces Preclinical Data Published Showing Ability Of Its Hypoimmune Allogeneic Cd19-Directed Car T Cells To Produce Durable Anti-Tumor Responses

Sana Biotechnology

13/04/2023 14:11

April 13 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY ANNOUNCES PRECLINICAL DATA PUBLISHED IN
NATURE COMMUNICATIONS DEMONSTRATING THE ABILITY OF ITS
HYPOIMMUNE ALLOGENEIC CD19-DIRECTED CAR T CELLS TO EVADE IMMUNE
REJECTION AND PRODUCE DURABLE ANTI-TUMOR RESPONSES
    * SANA BIOTECHNOLOGY INC - INITIAL CLINICAL DATA FROM SC291
IN
PATIENTS WITH B-CELL MALIGNANCIES EXPECTED LATER THIS YEAR

Source text for Eikon:  ID:nGNXxzYR8 
Further company coverage:  SANA.O 

 ((Reuters.Briefs@thomsonreuters.com;))